Argenx : Feu vert de la FDA pour Vyvgart Hytrulo dans la CIDP
>Vyvgart Hytrulo approuvé dans la CIDP - Vendredi soir dernier Vyvgart Hytrulo (version sous-cutanée de Vyvgart) a obtenu l’approbation de la FDA pour une utilisation dans la polyneuropathie inflammatoire démyélinisante chronique (CIDP), deuxième indication approuvée aux US après la Myasthénie Grave (MG). Le produit a obtenu un label large et pourra donc être prescrit chez tous les patients atteints de CIDP et tout au long de l’algorithme de traitement, ce que nous co...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.